{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:46:03Z","timestamp":1792089963012,"version":"4.4.0"},"reference-count":112,"publisher":"Harborside Press, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:p>The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non\u2013muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Gu\u00e9rin (BCG) shortage; new roles for immune checkpoint inhibitors in non\u2013muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody\u2013drug conjugates for metastatic bladder cancer.<\/jats:p>","DOI":"10.6004\/jnccn.2022.0041","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T15:36:04Z","timestamp":1660145764000},"page":"866-878","source":"Crossref","is-referenced-by-count":277,"title":["NCCN Guidelines\u00ae Insights: Bladder Cancer, Version 2.2022"],"prefix":"10.6004","volume":"20","author":[{"given":"Thomas W.","family":"Flaig","sequence":"first","affiliation":[{"name":"1University of Colorado Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[{"name":"2Moffitt Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Abern","sequence":"additional","affiliation":[{"name":"3Duke Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"4Huntsman Cancer Institute at the University of Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Bangs","sequence":"additional","affiliation":[{"name":"5Patient advocate;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Boorjian","sequence":"additional","affiliation":[{"name":"6Mayo Clinic Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K.","family":"Buyyounouski","sequence":"additional","affiliation":[{"name":"7Stanford Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Chan","sequence":"additional","affiliation":[{"name":"8City of Hope National Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Chang","sequence":"additional","affiliation":[{"name":"9Vanderbilt-Ingram Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Friedlander","sequence":"additional","affiliation":[{"name":"10UCSF Helen Diller Family Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"11Fox Chase Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurshid A.","family":"Guru","sequence":"additional","affiliation":[{"name":"12Roswell Park Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry W.","family":"Herr","sequence":"additional","affiliation":[{"name":"13Memorial Sloan Kettering Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Hoffman-Censits","sequence":"additional","affiliation":[{"name":"14The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Kishan","sequence":"additional","affiliation":[{"name":"15UCLA Jonsson Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilajit","family":"Kundu","sequence":"additional","affiliation":[{"name":"16Robert H. Lurie Comprehensive Cancer Center of Northwestern University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh M.","family":"Lele","sequence":"additional","affiliation":[{"name":"17Fred & Pamela Buffett Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[{"name":"18Abramson Cancer Center at the University of Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaly","family":"Margulis","sequence":"additional","affiliation":[{"name":"19UT Southwestern Simmons Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Y.","family":"Mian","sequence":"additional","affiliation":[{"name":"20Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Michalski","sequence":"additional","affiliation":[{"name":"21Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Montgomery","sequence":"additional","affiliation":[{"name":"22University of Michigan Rogel Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshminarayanan","family":"Nandagopal","sequence":"additional","affiliation":[{"name":"23O\u2019Neal Comprehensive Cancer Center at UAB;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance C.","family":"Pagliaro","sequence":"additional","affiliation":[{"name":"6Mayo Clinic Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Parikh","sequence":"additional","affiliation":[{"name":"24UC Davis Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Patterson","sequence":"additional","affiliation":[{"name":"25St. Jude Children\u2019s Research Hospital\/The University of Tennessee Health Science Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Plimack","sequence":"additional","affiliation":[{"name":"11Fox Chase Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal S.","family":"Pohar","sequence":"additional","affiliation":[{"name":"26The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Preston","sequence":"additional","affiliation":[{"name":"27Dana-Farber\/Brigham and Women\u2019s Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Richards","sequence":"additional","affiliation":[{"name":"28University of Wisconsin Carbone Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade J.","family":"Sexton","sequence":"additional","affiliation":[{"name":"2Moffitt Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene O.","family":"Siefker-Radtke","sequence":"additional","affiliation":[{"name":"29The University of Texas MD Anderson Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Tollefson","sequence":"additional","affiliation":[{"name":"6Mayo Clinic Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Tward","sequence":"additional","affiliation":[{"name":"4Huntsman Cancer Institute at the University of Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Wright","sequence":"additional","affiliation":[{"name":"30Fred Hutchinson Cancer Research Center\/Seattle Cancer Care Alliance; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"Dwyer","sequence":"additional","affiliation":[{"name":"31National Comprehensive Cancer Network."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly J.","family":"Cassara","sequence":"additional","affiliation":[{"name":"31National Comprehensive Cancer Network."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Gurski","sequence":"additional","affiliation":[{"name":"31National Comprehensive Cancer Network."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref571","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref1171","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.20.01665","article-title":"Radical cystectomy against intravesical BCG for High-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study","volume":"39","author":"Catto","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","article-title":"Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Gu\u00e9rin (BCG) in patients with non-muscle-invasive bladder carcinoma","volume":"52","author":"Friedrich","year":"2007","journal-title":"Eur Urol"},{"key":"ref1151","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0895-4356(99)00203-6","article-title":"Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials","volume":"53","author":"Huncharek","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.20.01665","article-title":"Radical cystectomy against intravesical BCG for High-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study","volume":"39","author":"Catto","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0895-4356(99)00203-6","article-title":"Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials","volume":"53","author":"Huncharek","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Gu\u00e9rin after initial bacille Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(17)30007-4","article-title":"Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study","volume":"18","author":"Plimack","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2005","journal-title":"J Urol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00005392-199907000-00018","article-title":"The value of a second transurethral resection in evaluating patients with bladder tumors","volume":"162","author":"Herr","year":"1999","journal-title":"J Urol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bju.14417","article-title":"A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens","volume":"123","author":"Mari","year":"2019","journal-title":"BJU Int"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"100369","DOI":"10.1016\/j.ctarc.2021.100369","article-title":"Active surveillance for non-muscle invasive bladder cancer: a systematic review and pooled-analysis","volume":"27","author":"Petrelli","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"9.e1","DOI":"10.1016\/j.urolonc.2021.03.024","article-title":"Intravesical sequential gemcitabine and docetaxel versus bacillus Calmette-Guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG","volume":"40","author":"Steinberg","year":"2022","journal-title":"Urol Oncol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11934-012-0234-4","article-title":"Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer","volume":"13","author":"Ram\u00edrez-Backhaus","year":"2012","journal-title":"Curr Urol Rep"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"ref1201","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.urolonc.2016.11.016","article-title":"Bacillus Calmette-Guerin strain may not affect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer","volume":"35","author":"Steinberg","year":"2017","journal-title":"Urol Oncol"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.euf.2021.03.016","article-title":"Intravesical therapy in patients with intermediate-risk non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of disease recurrence","volume":"8","author":"Laukhtina","year":"2022","journal-title":"Eur Urol Focus"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/JU.0000000000000593","article-title":"Use and validation of the AUA\/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort","volume":"203","author":"Ritch","year":"2020","journal-title":"J Urol"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2005","journal-title":"J Urol"},{"key":"ref281","first-page":"CD009294","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"1","author":"Jones","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"ref1251","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3233\/BLC-190236","article-title":"CIS of the bladder: significance and implications for therapy","volume":"5","author":"Mirabal","year":"2019","journal-title":"Bladder Cancer"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s10147-019-01581-0","article-title":"The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial","volume":"25","author":"Eroglu","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00345-009-0377-1","article-title":"The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience","volume":"27","author":"Barlow","year":"2009","journal-title":"World J Urol"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-170126","article-title":"Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer","volume":"3","author":"Milbar","year":"2017","journal-title":"Bladder Cancer"},{"key":"ref141","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis","volume":"21","author":"Huncharek","year":"2001","journal-title":"Anticancer Res"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3233\/BLC-190236","article-title":"CIS of the bladder: significance and implications for therapy","volume":"5","author":"Mirabal","year":"2019","journal-title":"Bladder Cancer"},{"key":"ref1261","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.urolonc.2008.11.019","article-title":"Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer","volume":"28","author":"Breyer","year":"2010","journal-title":"Urol Oncol"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/iju.12609","article-title":"Efficacy and tolerance of one-third full dose bacillus Calmette-Gu\u00e9rin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study","volume":"22","author":"Pfister","year":"2015","journal-title":"Int J Urol"},{"key":"ref1241","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref201","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.ju.0000070437.14275.e0","article-title":"Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study","volume":"170","author":"Grimm","year":"2003","journal-title":"J Urol"},{"key":"ref851","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0022-5347(05)01002-5","article-title":"The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial","volume":"175","author":"Divrik","year":"2006","journal-title":"J Urol"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.eururo.2018.06.024","article-title":"Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations","volume":"74","author":"Klaassen","year":"2018","journal-title":"Eur Urol"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.euf.2021.03.016","article-title":"Intravesical therapy in patients with intermediate-risk non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of disease recurrence","volume":"8","author":"Laukhtina","year":"2022","journal-title":"Eur Urol Focus"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"key":"ref931","first-page":"CD009294","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"1","author":"Jones","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"ref1221","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bju.14417","article-title":"A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens","volume":"123","author":"Mari","year":"2019","journal-title":"BJU Int"},{"key":"ref1291","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.eururo.2018.06.024","article-title":"Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations","volume":"74","author":"Klaassen","year":"2018","journal-title":"Eur Urol"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s10147-019-01581-0","article-title":"The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial","volume":"25","author":"Eroglu","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"9.e1","DOI":"10.1016\/j.urolonc.2021.03.024","article-title":"Intravesical sequential gemcitabine and docetaxel versus bacillus Calmette-Guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG","volume":"40","author":"Steinberg","year":"2022","journal-title":"Urol Oncol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0022-5347(05)01002-5","article-title":"The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial","volume":"175","author":"Divrik","year":"2006","journal-title":"J Urol"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(17)30007-4","article-title":"Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study","volume":"18","author":"Plimack","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.urolonc.2016.11.016","article-title":"Bacillus Calmette-Guerin strain may not affect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer","volume":"35","author":"Steinberg","year":"2017","journal-title":"Urol Oncol"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00005392-199907000-00018","article-title":"The value of a second transurethral resection in evaluating patients with bladder tumors","volume":"162","author":"Herr","year":"1999","journal-title":"J Urol"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.juro.2015.08.075","article-title":"Randomized controlled study of the efficacy, safety and quality of life with low dose bacillus Calmette-Gu\u00e9rin instillation therapy for nonmuscle invasive bladder cancer","volume":"195","author":"Yokomizo","year":"2016","journal-title":"J Urol"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.ju.0000136446.37840.0a","article-title":"Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer","volume":"172","author":"O\u2019Donnell","year":"2004","journal-title":"J Urol"},{"key":"ref791","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis","volume":"21","author":"Huncharek","year":"2001","journal-title":"Anticancer Res"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.urolonc.2008.11.019","article-title":"Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer","volume":"28","author":"Breyer","year":"2010","journal-title":"Urol Oncol"},{"key":"ref1131","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","article-title":"Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Gu\u00e9rin (BCG) in patients with non-muscle-invasive bladder carcinoma","volume":"52","author":"Friedrich","year":"2007","journal-title":"Eur Urol"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Gu\u00e9rin after initial bacille Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"ref1161","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"100369","DOI":"10.1016\/j.ctarc.2021.100369","article-title":"Active surveillance for non-muscle invasive bladder cancer: a systematic review and pooled-analysis","volume":"27","author":"Petrelli","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","article-title":"Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"197","author":"Chou","year":"2017","journal-title":"J Urol"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.ju.0000136446.37840.0a","article-title":"Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer","volume":"172","author":"O\u2019Donnell","year":"2004","journal-title":"J Urol"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","article-title":"Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"197","author":"Chou","year":"2017","journal-title":"J Urol"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11934-012-0234-4","article-title":"Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer","volume":"13","author":"Ram\u00edrez-Backhaus","year":"2012","journal-title":"Curr Urol Rep"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-170126","article-title":"Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer","volume":"3","author":"Milbar","year":"2017","journal-title":"Bladder Cancer"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/JU.0000000000000593","article-title":"Use and validation of the AUA\/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort","volume":"203","author":"Ritch","year":"2020","journal-title":"J Urol"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"ref1271","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: a phase i study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.juro.2015.08.075","article-title":"Randomized controlled study of the efficacy, safety and quality of life with low dose bacillus Calmette-Gu\u00e9rin instillation therapy for nonmuscle invasive bladder cancer","volume":"195","author":"Yokomizo","year":"2016","journal-title":"J Urol"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.ju.0000070437.14275.e0","article-title":"Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study","volume":"170","author":"Grimm","year":"2003","journal-title":"J Urol"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: a phase i study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00345-009-0377-1","article-title":"The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience","volume":"27","author":"Barlow","year":"2009","journal-title":"World J Urol"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/iju.12609","article-title":"Efficacy and tolerance of one-third full dose bacillus Calmette-Gu\u00e9rin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study","volume":"22","author":"Pfister","year":"2015","journal-title":"Int J Urol"},{"key":"ref1181","doi-asserted-by":"crossref","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/8\/article-p866.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/20\/8\/article-p866.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T14:27:04Z","timestamp":1660314424000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/8\/article-p866.xml"}},"subtitle":["Featured Updates to the NCCN Guidelines"],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":112,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2022.0041","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}